Evidence map›Paper›PMID 40328830›Full record

ArticleScientific reports2025

Genome-wide DNA methylation analysis of Astragalus on the intervention of ID2 promoter via PI3K/Akt signaling pathway in peritoneal fibrosis.

Manshu Yu, Junyi Zhao, Yun Shan, Huibo Dai, Lei Tang, Li Sheng, Lu Zhang, Meixiao Sheng

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Manshu YuRenal Division, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210029, China.
Junyi ZhaoInstitute of Literature in Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Yun ShanRenal Division, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210029, China.
Huibo DaiRenal Division, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210029, China.
Lei TangRenal Division, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210029, China.
Li ShengRenal Division, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210029, China.
Lu ZhangRenal Division, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210029, China. zhanglu@njucm.edu.cn.
Meixiao ShengRenal Division, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210029, China. yfy0075@njucm.edu.cn.

Funding

Jiangsu Province Hospital of Chinese Medicine Peak Talent Program Y2021RC10National Natural Science Foundation of China 81774253National Natural Science Foundation of China 82004295Natural Science Foundation of Jiangsu Province BK20171514Natural Science Foundation of Jiangsu Province BK20211393Outstanding Young Doctor's Fund of Jiangsu Province Hospital of Chinese Medicine 2023QB0133
6 · The paper itself

Abstract

Peritoneal dialysis (PD) is a successful renal replacement therapy for end-stage renal disease. Continuous infiltration of bioincompatible PD fluid causes mesothelial-mesenchymal transition (MMT) of peritoneal mesothelial cells (PMCs), leading to peritoneal fibrosis (PF). DNA methylation has been characterized as an important regulatory mechanism on multiple fibrosis. However, the mechanisms by which DNA methylation regulates PF are not fully understood resulting in a lack of disease-modifying drugs. Astragalus membranaceus (Astragalus) is naturally phytomedicine that has immunoregulation properties. The study aimed to elucidate the underlying mechanisms of Astragalus in regulating DNA methylation and anti-PF capabilities. In vivo PD rat models were established by inducing with high-glucose PD fluid and Astragalus was intraperitoneal injection. Global DNA methylation sequencing was used to compare the DNA methylation status between control and PF rat models. Methylation profiles and KEGG analysis were identified a possible methylated target gene and its correlation pathway. Through real-time PCR and western blotting, candidate markers and pathways were validated in vivo and in vitro. Chromatin immunoprecipitation and luciferase assays were used to identify the prediction of DNA methyltransferase (Dnmts) binding with methylated target gene. The functions of the validated pathways were further investigated using the knockdown or overexpression strategy. In vivo and in vitro, Astragalus treatment showed a protective effect against PF and Dnmts, characterized by improving pathological manifestation, ameliorating MMT markers, and reducing Dnmt1/3a proteins. Inhibitor of DNA-binding 2 (ID2) was investigated in target gene by integrating the mRNA and methylation profiles involved in PF and Astragalus treatment. PF induced the methylation of ID2 that resulted in recruitment of the Dnmt3a and decreased ID2 expression. The increased ID2 expression in response to Astragalus is a consequence of demethylation in promoter. In addition, phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway correlated with PF, knockdown or overexpression of ID2 regulated this pathway and MMT of PMCs. Astragalus ameliorated PF by targeting Dnmt3a mediated ID2 promoter via PI3K/Akt signaling pathway. The epigenetic regulation of DNA methylation existed the critical role in attenuating PF.

Indexed as

Astragalus PlantDNA MethylationInhibitor of Differentiation Protein 2Peritoneal FibrosisPhosphatidylinositol 3-KinasesPlant ExtractsPromoter Regions, GeneticProto-Oncogene Proteins c-aktSignal TransductionAnimalsDisease Models, AnimalDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3AMalePeritoneal DialysisRatsDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3AInhibitor of Differentiation Protein 2Phosphatidylinositol 3-KinasesPlant ExtractsProto-Oncogene Proteins c-aktAstragalusDNA methylationInhibitor of DNA-binding 2Mesothelial-mesenchymal transitionPeritoneal fibrosis

Identifiers

PMID40328830
PMCPMC12056223

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.